Please assess the completion status of the following clinical trial:

Trial Title: HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 seropositive~* HSV-2 seropositive~* Plans to deliver in Nairobi~* Resides and plans to remain in Nairobi for 12 months postpartum~* 18 years of age or older~* CD4 count\>250 cells/μl~Exclusion Criteria:~* indication for highly active antiretroviral therapy (e.g., WHO stage III or IV)~* hypersensitivity to valacyclovir or acyclovir

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
- 2 (Type: PLACEBO_COMPARATOR): oral placebo twice daily from 34 weeks gestation to 1 year postpartum

Based on this trial design, predict the completion outcome and termination type (if applicable).